SEC Form 4 · accession 0001144204-17-026826
INTERLEUKIN GENETICS INC · ILIU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephan Toutain
Officer — Chief Commercial Officer
Period of report
Apr 19, 2017
Accepted (ET)
May 12, 2017 · 2:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001037649
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $0.095 | Apr 19, 2017 | A | 182,547 | A | — | Apr 19, 2027 | Common Stock | 182,547 | 182,547 | D |
Explanation of responses
- F1The exercise price of the option is the closing price of the Issuer's common stock on the OTCQB on April 19, 2017, which was the grant date of the option.
- F2The option vests as to 25% of the shares on April 19, 2018, and 1/36th of the shares on the first day of each month beginning on May 1, 2018.